drugset / Trial / NCT06703047
Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
RandomizedParallel-groupDouble-blindTreatment
Summary
Tislelizumab combined with chemotherapy and all trans retinoic acid for locally advanced or metastatic esophageal squamous cell carcinoma: a prospective, double-blind, multicenter, randomized controlled phase II trial
Timeline
- Start
- 2024-11-20
- Primary completion
- 2029-11-20
- Completion
- 2030-10-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tretinoin | Unknown | — | — |
| Comparator | Carboplatin | Small molecule | — | — |
| Comparator | Cisplatin | Other / unclassified | — | — |
| Comparator | Paclitaxel | Small molecule | — | — |
| Comparator | Tislelizumab | Monoclonal antibody | — | — |